コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 the subset of African American patients with anti-CCP antibodies.
2 igher titers of autoantibodies, particularly anti-CCP antibodies.
3 ve patients with polyarticular-onset JRA had anti-CCP antibodies.
4 ted with presence of the SE independently of anti-CCP antibodies.
5 isotypes, anti-cyclic citrullinated peptide (anti-CCP) antibodies, 14 cytokines and chemokines (by be
6 sociation of the SE with the presence of the anti-CCP antibody: 86 (48.9%) of 176 patients with anti-
7 esence, development, and extent of erosions, anti-CCP antibodies alone are not a sufficiently accurat
11 e sibling had significantly higher titers of anti-CCP antibodies and were more likely to be SE positi
15 0 participants and that examined the role of anti-CCP antibody and RF in the diagnosis or prognosis o
16 ested for anti-cyclic citrullinated peptide (anti-CCP) antibodies and anti-mycobacterial Hsp65 antibo
17 levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies and current use of biologic agents,
18 of serum anti-cyclic citrullinated peptide (anti-CCP) antibodies and HLA-DRB1 genotyping, a panel of
20 in children with polyarticular JRA, whether anti-CCP antibodies are associated with clinical feature
21 Our objectives were to determine whether anti-CCP antibodies are associated with HLA-DR4 in child
27 titers of anti-cyclic citrullinated peptide (anti-CCP) antibodies compared with female patients, even
28 A and 2% of the other JRA patients exhibited anti-CCP antibodies, compared with only 0.6% of the cont
29 s, the levels of IgA-RF, IgG-RF, and IgG and anti-CCP antibodies decreased significantly more than di
30 h anti-CCP- disease and with lower levels of anti-CCP antibodies, even when controlling for the SE.
33 were to examine the role of baseline RF and anti-CCP antibodies in determining the likelihood of pat
36 els were investigated to examine the role of anti-CCP antibodies in patients stratified by RF status.
37 (hsCRP), anti-cyclic citrullinated peptide (anti-CCP) antibodies, interleukin-6 (IL-6), and soluble
38 However, the combination of SE, smoking, and anti-CCP antibodies is associated with a high risk of pr
40 2%) experienced a > or =25% reduction in the anti-CCP antibody level during the course of treatment,
48 ompared with 36 (32.7%) of 110 patients with anti-CCP antibody-negative RA (P = 0.01, by chi-square t
49 A directly correlated with the levels of the anti-CCP antibodies, of the Th1/Th17 cytokines, and of t
50 radiologic damage, and to determine whether anti-CCP antibodies or RF is sufficiently robust to be c
51 alysis, factors associated with SSc-ILD were anti-CCP antibody or rheumatoid factor (beta coefficient
52 ly associated with a decline in the level of anti-CCP antibody (OR 3.0, 95% CI 1.0-8.8), and no assoc
54 pneumonia (UIP) incidence was higher in the anti-CCP antibody-positive group than in the anti-CCP an
55 CP antibody: 86 (48.9%) of 176 patients with anti-CCP antibody-positive RA had at least 1 SE allele,
57 or radiographic progression was greater with anti-CCP antibody positivity than with IgM RF positivity
59 f association of these genotypes with RF and anti-CCP antibody status suggests that they act downstre
62 articular-onset JRA were more likely to have anti-CCP antibodies than were those without HLA-DR4 alle
64 sex, age, anti-cyclic citrullinated peptide (anti-CCP) antibody titer, disease duration, and C-reacti
65 f the SE did not fully explain the increased anti-CCP antibody titers observed in these families.
66 , and IgG anti-cyclic citrullinated peptide (anti-CCP) antibodies together with an elevated C-reactiv
67 elevated level of any RF isotype and/or IgG anti-CCP antibodies was further associated with an enhan
68 An interaction of smoking, SE alleles, and anti-CCP antibodies was observed and was associated with
70 positive and negative likelihood ratios for anti-CCP antibody were 67% (95% CI, 62% to 72%), 95% (CI
71 ssociated with seropositivity for RF and the anti-CCP antibody, which was highly relevant given the a
72 s at risk for developing RA, with or without anti-CCP antibodies, whose first-degree relatives have b